Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Cybersecurity ETF vs Zoetis Inc — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $100.33, while Zoetis Inc trades at $72.41 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while First Trust NASDAQ Cybersecurity ETF pays none, and First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| CIBR | ZTS | |
|---|---|---|
52-Week High | $100.60 | $156.76 |
52-Week Low | $60.74 | $71.91 |
Market Cap | — | $31.14B |
Sector | — | Health |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CIBR trades at $100.86, up 0.26% today, with strong bullish momentum from moving averages but overbought RSI signals. The cybersecurity ETF has outperformed the S&P 500 by 3:1 year-to-date, benefiting from AI-driven security spending growth exceeding $300 billion in 2026. Recent institutional activity shows mixed sentiment with Bank of America reducing its stake while First Trust Advisors increased its position by 12.4%.
Outlook remains positive given cybersecurity's essential role in AI expansion, though high RSI levels suggest near-term consolidation risk. The sector's defensive growth characteristics and increasing attack surfaces provide long-term tailwinds, but concentrated tech exposure and valuation concerns warrant monitoring.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
